Kramer DB, Kesselheim AS - New England Journal of Medicine
- Commentary & Opinion
- Regulation and Clinical Evidence
Summary:
The authors discuss the Affordable Care Act’s 2.3% medical device excise tax and the intense industry lobbying that led to an overwhelming Senate vote for repeal, questioning whether the industry’s claims about job losses and innovation impacts were supported by evidence.
VIEW SOURCE
Recent Work from PORTAL
How Congress Can Fix Expert Advisory Committees
Daval CJR, Kesselheim AS - STAT
- Commentary & Opinion
- Regulation and Clinical Evidence
International Regulatory Status and Reimbursement Recommendations of Haematological Malignancy Drugs Withdrawn from the FDA Accelerated Approval Pathway
Mulsant SS, Kesselheim AS, Naci H - Journal of Cancer Policy
- Research Publications
- Price, Value, and Access
- Regulation and Clinical Evidence
The Impact of Semantics in Medicines Regulation
Costa E, Kesselheim AS - Journal of Law, Medicine, & Ethics
- Commentary & Opinion
- Innovation Incentives and Competition
- Regulation and Clinical Evidence
Program On Regulation, Therapeutics, And Law (PORTAL)
Division of Pharmacoepidemiology and Pharmacoeconomics
Brigham and Women's Hospital • Harvard Medical School
41 Avenue Louis Pasteur, Suite 0B17, Boston, MA 02115
©2026 Program On Regulation, Therapeutics, And Law (PORTAL). All rights reserved.